GlassScriptPhysician profile
Phyllis P Birkel
NPI 1871657643
$14,493.07
in general payments reported to CMS, 2019-2025
30 companies · $2,167 in 2025
The $2,167 reported for 2025 was more than what a typical Rheumatology provider received nationally (typical 2025 total: $894).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,890 · 2020: $1,302 · 2021: $2,166 · 2022: $2,064 · 2023: $2,319 · 2024: $2,585 · 2025: $2,167.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,745 · Education: $326.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,744.52 |
| Education | $326.27 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $2,561.61 | 2019-2025 | Tavneos, Enbrel, Otezla |
| Abbvie INC. | $2,411.86 | 2019-2025 | Rinvoq, Skyrizi |
| Janssen Biotech, INC. | $2,116.68 | 2019-2025 | Tremfya, Simponi Aria, Stelara |
| Novartis Pharmaceuticals Corporation | $1,355.66 | 2019-2025 | |
| Ucb, INC. | $1,348.72 | 2019-2025 | Cimzia, Bimzelx |
| E.R. Squibb & Sons, L.L.C. | $951.66 | 2019-2025 | Orencia |
| Pfizer INC. | $913.63 | 2019-2025 | |
| Glaxosmithkline, LLC. | $727.13 | 2019-2025 | Benlysta, Nucala |
| Lilly USA, LLC | $587.52 | 2019-2023 | Taltz |
| Horizon Therapeutics Plc | $241.48 | 2019-2023 | Krystexxa |
| Mallinckrodt Hospital Products INC. | $228.42 | 2021-2024 | Acthar |
| Boehringer Ingelheim Pharmaceuticals, INC. | $168.07 | 2020-2025 | Ofev, Cyltezo |
| Fresenius Kabi USA, LLC | $135.64 | 2023 | Idacio |
| Sobi, INC | $99.75 | 2019-2024 | |
| Radius Health, INC. | $81.87 | 2019-2025 | Tymlos |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $77.70 | 2022-2024 | |
| Alexion Pharmaceuticals, INC. | $77.68 | 2019-2024 | Strensiq |
| Aurinia Pharma U.S., INC. | $74.53 | 2023-2025 | Lupkynis |
| Antares Pharma, INC. | $55.89 | 2019 | |
| Alvogen INC | $45.84 | 2025 | Teriparatide |
| Actelion Pharmaceuticals US, INC. | $36.28 | 2019-2022 | |
| Sandoz INC. | $28.51 | 2023 | Hyrimoz |
| Pacira Therapeutics, INC. | $27.68 | 2019 | |
| Kyowa Kirin, INC. | $25.12 | 2025 | |
| Qiagen, LLC | $22.71 | 2021 | |
| Kiniksa Pharmaceuticals International, Plc | $21.54 | 2024 | Arcalyst |
| Regeneron Healthcare Solutions, INC. | $19.53 | 2019 | |
| Arcutis Biotherapeutics, INC. | $17.78 | 2023 | |
| Mallinckrodt Enterprises LLC | $16.92 | 2019 | |
| Organon LLC | $15.66 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Phyllis Birkel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.